Alphamab Oncology (HKG:9966) said it dosed the first patient in the Phase 1 study of JSKN027, according to a Hong Kong bourse filing Monday.
Shares of the firm gained nearly 2% in late morning trade Tuesday.
JSKN027 is a first-in-class bispecific antibody-drug conjugate (ADC) targeting PD-L1 and VEGFR2.
The company will study the safety and preliminary anti-tumor activity of JSKN027 in an open-label clinical trial.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.